Hannes Merten

Title: Hannes Merten: Innovator in Cancer Treatment

Introduction

Hannes Merten is a prominent inventor based in Zürich, Switzerland. He has made significant contributions to the field of cancer treatment through his innovative work on antigen binding proteins. His research focuses on the development of dual T cell engagers that target specific cancer antigens.

Latest Patents

Hannes Merten holds 1 patent for his invention titled "MAGE-A4 peptide dual T cell engagers." This patent describes antigen binding proteins that specifically target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). The invention also includes multispecific antigen binding proteins that comprise an antigen binding domain with specificity to CD3, along with at least one MAGE-A4 pMHC antigen binding domain. Furthermore, the patent outlines methods for treating cancer using these innovative proteins.

Career Highlights

Hannes Merten is associated with Cdr-life AG, a company dedicated to advancing cancer therapies. His work has positioned him as a key figure in the development of novel treatments that harness the immune system to combat cancer effectively.

Collaborations

Hannes collaborates with talented individuals such as Stephanie Jungmichel and Fabian Bert Scheifele. Their combined expertise contributes to the innovative research and development efforts at Cdr-life AG.

Conclusion

Hannes Merten's contributions to cancer treatment through his patented innovations highlight the importance of research in developing effective therapies. His work continues to inspire advancements in the field of oncology.